PTC Therapeutics’ stock narrative has shifted as analysts raise their consensus price target from $77.93 to $80.50. This reflects heightened optimism around the company’s outlook. This change comes in the wake of strong earnings results…
How The Sephience Launch Is Reshaping The Story For PTC Therapeutics’s Valuation
